Benjamin Hohl - Oct 4, 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Benjamin Hohl
Stock symbol
ELVN
Transactions as of
Oct 4, 2024
Transactions value $
-$287,524
Form type
4
Date filed
10/8/2024, 06:56 PM
Previous filing
Oct 3, 2024
Next filing
Oct 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $25.3K +10.2K $2.48 10.2K Oct 4, 2024 Direct F1
transaction ELVN Common Stock Sale -$281K -10.2K -100% $27.51 0 Oct 4, 2024 Direct F1, F2
transaction ELVN Common Stock Options Exercise $3.15K +1.27K +173.97% $2.48 2K Oct 7, 2024 Direct F1
transaction ELVN Common Stock Sale -$34.9K -1.27K -100% $27.51 0 Oct 7, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Options Exercise $0 -10.2K -5.31% $0.00 182K Oct 4, 2024 Common Stock 10.2K $2.48 Direct F1, F4
transaction ELVN Stock Option (right to buy) Options Exercise $0 -1.27K -0.7% $0.00 181K Oct 7, 2024 Common Stock 1.27K $2.48 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $27.50 to $27.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $27.50 to $27.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.